Last updated: April 1, 2026
What is NDC 76329-3013?
NDC 76329-3013 refers to a specific prescription drug listed in the National Drug Code (NDC) system. The product identified by this code is Vabysmo (faricimab-svoa), a bi-specific antibody developed by Roche used to treat wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Vabysmo is approved by the FDA since January 2022.
Market Landscape
Key Indications
Vabysmo targets two leading ocular conditions:
- Wet AMD
- Diabetic Macular Edema (DME)
Market Size
The global market for ocular anti-VEGF therapies, which includes Vabysmo, is significant. The market was valued at approximately USD 8.1 billion in 2022 and expected to grow at around 6% annually through 2028 [1].
In the U.S., approximately 2 million Americans diagnosed with AMD and 4 million with DME create a substantial patient population. These figures translate to an annual treatment market that could reach USD 3-4 billion in the U.S. alone by 2028.
Competitor Landscape
Vabysmo competes with established therapies such as:
- Lucentis (ranibizumab)
- Eylea (aflibercept)
- Beovu (brolucizumab)
Market share distribution in 2022:
| Drug |
Market Share |
Annual Revenue (USD) |
Key Features |
| Eylea |
45% |
3.6 billion |
Broadest indications, established |
| Lucentis |
30% |
2.4 billion |
First approved, high efficacy |
| Beovu |
10% |
800 million |
Longer dosing, safety concerns |
| Vabysmo |
15% |
Estimated 600 million |
New entrant, potential shift |
Distribution and Adoption
Initial adoption is driven by the drug’s clinical profile and dosing advantages. Vabysmo's ability to reduce injection frequency could influence patient compliance and healthcare costs.
Price Structure and Cost Dynamics
Wholesale Acquisition Cost (WAC) and List Prices
In the U.S., the average wholesale price (AWP) for comparable anti-VEGF agents ranges from USD 1,800 to USD 2,200 per injection. Vabysmo's list price per injection is approximately USD 2,100.
Cost per Treatment Course
Typically, treatment involves monthly injections for the first three months, followed by dosing intervals of 2 to 4 months:
| Treatment Phase |
Number of Injections |
Estimated Cost (USD) |
| Initial loading |
3 |
6,300 |
| Maintenance (annual) |
4-6 per year |
8,400 - 12,600 |
Reimbursement and Market Penetration
Reimbursement rates often match list prices, but discounts and rebates reduce net costs. Payers' willingness to switch from entrenched therapies to Vabysmo depends on perceived value and clinical outcomes.
Pricing Projections (2023-2028)
| Year |
Estimated Price per Injection (USD) |
Assumptions |
| 2023 |
2,100 |
Launch phase, competition intensifies |
| 2024 |
2,050 |
Slight downward pressure, early volume growth |
| 2025 |
2,000 |
Increased adoption, payer negotiations |
| 2026 |
1,950 |
Market share stabilizes, generic or biosimilar competition emerges |
| 2027 |
1,900 |
Price erosion continues, pushing toward lower-cost options |
| 2028 |
1,850 |
Mature market, standardization, increased biosimilar presence |
Volume Growth Projections
Initial penetration is modest, capturing 5-10% of the anti-VEGF market in 2023. By 2028, Vabysmo could reach 25-30% market share, with global sales approaching USD 1.5-2 billion. Key factors include:
- Clinical advantages
- Dosing interval improvements
- Payer acceptance
Regulatory and Policy Considerations
- FDA approval since January 2022 for both indications.
- EU approval granted mid-2022.
- Reimbursement policies currently favor established therapies; reimbursement for new entrants relies on demonstrated cost savings and efficacy.
Risks and Opportunities
Risks
- Entrenched brand loyalty favors existing treatments.
- Disruption if biosimilars undercut pricing.
- Potential safety concerns or adverse events affecting uptake.
Opportunities
- Clinical data supporting improved compliance.
- Long-acting formulations further reducing treatment burden.
- Expansion into other ocular or systemic indications.
Key Takeaways
- The global anti-VEGF market exceeds USD 8 billion, with Vabysmo representing a promising entrant.
- Price per injection is expected to decline gradually from USD 2,100 to around USD 1,850 over five years.
- Market penetration will depend on clinical performance, payer acceptance, and pricing strategies.
- Revenue potential could approach USD 2 billion annually by 2028, assuming competitive positioning and increased adoption.
- Pricing strategies should align with clinical advantages and payer negotiations to maximize market share.
FAQs
1. How does Vabysmo's pricing compare to competitors?
Vabysmo's list price per injection is approximately USD 2,100, similar to Eylea and Beovu but higher than Lucentis. Actual net prices may be lower due to rebates.
2. What factors could influence Vabysmo's market share?
Clinical efficacy, dosing convenience, safety profile, payer reimbursement policies, and competitive biosimilar entries.
3. Is Vabysmo likely to sustain its market position beyond five years?
Yes, if it demonstrates superior efficacy, safety, and dosing frequency, its market share could grow despite pricing pressures.
4. What role do biosimilars play in price projections?
Biosimilars are expected to enter the market around 2025-2026, exerting downward pressure on prices and accelerating generic competition.
5. What are the major regulatory factors affecting Vabysmo?
FDA approval since 2022 for wet AMD and DME; eventual approval in other markets; reimbursement policies influence adoption.
References
- Market Research Future. (2022). Global Anti-VEGF Therapy Market Report.
